CRISPR Therapeutics AG (CRSP) last year’s performance of 43.94% is a clear signal for an entertaining trading season.

CRISPR Therapeutics AG (NASDAQ: CRSP) on Tuesday, plunged -4.62% from the previous trading day, before settling in for the closing price of $68.18. Within the past 52 weeks, CRSP’s price has moved between $37.55 and $91.10.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Healthcare Sector giant saw their annual sales surged by 33402.13% over the last five years. The company achieved an average annual earnings per share of -199.14%. With a float of $79.80 million, this company’s outstanding shares have now reached $80.04 million.

The firm has a total of 407 workers. Let’s measure their productivity.

CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CRISPR Therapeutics AG is 5.21%, while institutional ownership is 64.26%. The most recent insider transaction that took place on Mar 15 ’24, was worth 1,449,628. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $72.48, taking the stock ownership to the 208,122 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Financial Officer sold 3,524 for $72.69, making the entire transaction worth $256,160. This insider now owns 6,476 shares in total.

CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights

As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported $1.1 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.07) by $1.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.52 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -199.14% per share during the next fiscal year.

CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators

CRISPR Therapeutics AG (CRSP) is currently performing well based on its current performance indicators. A quick ratio of 17.54 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.75.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.97, a number that is poised to hit -1.45 in the next quarter and is forecasted to reach -4.08 in one year’s time.

Technical Analysis of CRISPR Therapeutics AG (CRSP)

Analysing the last 5-days average volume posted by the [CRISPR Therapeutics AG, CRSP], we can find that recorded value of 1.27 million was lower than the volume posted last year of 1.95 million. As of the previous 9 days, the stock’s Stochastic %D was 10.70%. Additionally, its Average True Range was 3.25.

During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 38.73%, which indicates a significant increase from 6.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.27% in the past 14 days, which was lower than the 66.27% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $73.68, while its 200-day Moving Average is $59.33. Now, the first resistance to watch is $66.19. This is followed by the second major resistance level at $67.36. The third major resistance level sits at $68.32. If the price goes on to break the first support level at $64.06, it is likely to go to the next support level at $63.10. Now, if the price goes above the second support level, the third support stands at $61.93.

CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats

Market capitalization of the company is 5.47 billion based on 80,276K outstanding shares. Right now, sales total 371,210 K and income totals -153,610 K. The company made 201,210 K in profit during its latest quarter, and 89,350 K in sales during its previous quarter.